Hyzetimibe

Summary

Hyzetimibe (CHEMBL4297389) is a phase-3 clinical-stage small molecule; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 4
• Chemistry: 421.4 Da · C25H21F2NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297389
Name	Hyzetimibe
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	50923862
Molecular formula	C25H21F2NO3
Molecular weight	421.4
InChIKey	HEHHPZYUXSFAPV-SMOXZEHUSA-N

SMILES: C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)C/C=C(\CO)/C4=CC=C(C=C4)F)O

IUPAC name: (3R,4S)-1-(4-fluorophenyl)-3-[(Z)-3-(4-fluorophenyl)-4-hydroxybut-2-enyl]-4-(4-hydroxyphenyl)azetidin-2-one

Also known as: Hs-25, HS-25, Hybutimibe, Hyzetimibe, HYZETIMIBE

Patent coverage: 25 distinct patent families (54 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03413462	PHASE3	COMPLETED	Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia
NCT03433196	PHASE3	COMPLETED	Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases
NCT03464682	PHASE3	UNKNOWN	Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia
NCT02087917	PHASE2	COMPLETED	A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).